Statement on Medicare Proposal to Limit Aduhelm Coverage
ACHP’s responds to Medicare’s proposal to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm.
ACHP’s responds to Medicare’s proposal to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm.
HealthLeaders recognizes ACHP and its members for innovation and recommendations on telehealth, drug pricing, health equity, access and more.
ACHP’s Ceci Connolly discusses the Build Back Better Act, ACA enrollment, drug pricing and more on KHN’s What the Health? podcast.
Besides being outrageously priced, Aduhelm is an unproven, potentially dangerous drug—a drug Medicare simply should not cover.
Sen. Cortez Masto, Rep. Bilirakis and Rep. Kind are honored as legislative champions for commitment to high-quality health coverage and care.
ACHP is the voice of a unique approach in health care today, one that puts the patient at the center with plans and clinical teams collaborating to improve health outcomes and reduce costs. Our advocacy focuses on providing policymakers with tested solutions, rooted in a model that is proven to deliver better value for patients, employers and taxpayers.